EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 274 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR How a Musician Copes With Life With Metastatic Breast Cancer March 17, 2021 Young Breast Cancer Survivor Killed in Hit and Run Crash Weeks... August 25, 2021 A real Eureka moment for translation February 10, 2023 The Horror Story Of What Can Happen When You Don’t Pay... September 16, 2019 Load more HOT NEWS News digest – sponge on a string, junk food watershed, prostate... The digital shift: How are remote GP appointments affecting cancer patients? EMA Recommends to Extend the Indications for Tislelizumab “Glossy” Awareness Campaigns Weren’t Representing Her Cancer, So She Started #TrueCancerBodies
